佩索利单抗成功治疗合并系统性红斑狼疮的泛发性脓疱型银屑病1例

doi:10.35541/cjd.20240305

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (8): 771-773.doi: 10.35541/cjd.20240305

佩索利单抗成功治疗合并系统性红斑狼疮的泛发性脓疱型银屑病1例

侯晓媛¹ 陈佳¹ 史玉玲²

¹上海市皮肤病医院同济大学附属皮肤病医院风湿免疫科，上海 200040；²上海市皮肤病医院同济大学附属皮肤病医院皮肤内科，上海 200040

收稿日期:2024-06-07 修回日期:2024-10-18 发布日期:2025-08-05
通讯作者: 陈佳 E-mail:1500155@tongji.edu.cn

Spesolimab for the successful treatment of generalized pustular psoriasis complicated by systemic lupus erythematosus: a case report

Hou Xiaoyuan¹, Chen Jia¹, Shi Yuling²

¹Department of Rheumatology, Shanghai Skin Disease Hospital, Skin Disease Hospital of Tongji University, Shanghai 200040, China; ²Department of Dermatology, Shanghai Skin Disease Hospital, Skin Disease Hospital of Tongji University, Shanghai 200040, China

Received:2024-06-07 Revised:2024-10-18 Published:2025-08-05
Contact: Chen Jia E-mail:1500155@tongji.edu.cn

摘要/Abstract

摘要： 患者女，32岁，因面部、胸部散在红斑、脓疱4 d于2023年7月13日入上海市皮肤病医院住院。10余年前（2012年）患者因妊娠体检发现血小板减少……

侯晓媛陈佳史玉玲. 佩索利单抗成功治疗合并系统性红斑狼疮的泛发性脓疱型银屑病1例[J]. 中华皮肤科杂志, 2025,58(8):771-773. doi:10.35541/cjd.20240305

Hou Xiaoyuan, Chen Jia, Shi Yuling. Spesolimab for the successful treatment of generalized pustular psoriasis complicated by systemic lupus erythematosus: a case report[J]. Chinese Journal of Dermatology, 2025, 58(8): 771-773.doi:10.35541/cjd.20240305

参考文献 8

［1］	Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis［J］. Am J Clin Dermatol, 2022,23（Suppl 1）:21⁃29. doi: 10.1007/s40257⁃021⁃00654⁃z.
［2］	Zhou J, Luo Q, Cheng Y, et al. An update on genetic basis of generalized pustular psoriasis （review）［J］. Int J Mol Med, 2021,47（6）:118 ［pii］. doi: 10.3892/ijmm.2021.4951.
［3］	Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?［J］. J Eur Acad Dermatol Venereol, 2013,27（8）:1022⁃1025. doi: 10.1111/j.1468⁃3083. 2012.04656.x.
［4］	Blair HA. Spesolimab: first approval［J］. Drugs, 2022,82（17）:1681⁃1686. doi: 10.1007/s40265⁃022⁃01801⁃4.
［5］	Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 phaseⅡ, multicentre, randomised, double⁃blind, placebo⁃controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare［J］. BMJ Open, 2021,11（3）:e043666. doi: 10.1136/bmjopen⁃2020⁃043666.
［6］	Navarini AA, Prinz JC, Morita A, et al. Spesolimab improves patient⁃reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:730⁃736. doi: 10.1111/jdv. 18820.
［7］	Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis［J］. N Engl J Med, 2021,385（26）:2431⁃2440. doi: 10.1056/NEJMoa2111563.
［8］	Mai SZ, Li CJ, Xie XY, et al. Increased serum IL⁃36α and IL⁃36γ levels in patients with systemic lupus erythematosus: association with disease activity and arthritis［J］. Int Immunopharmacol, 2018,58:103⁃108. doi: 10.1016/j.intimp.2018.03.011.

佩索利单抗成功治疗合并系统性红斑狼疮的泛发性脓疱型银屑病1例

Spesolimab for the successful treatment of generalized pustular psoriasis complicated by systemic lupus erythematosus: a case report

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 8

相关文章 0

Metrics

本文评价

推荐阅读 10